What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers
Companies receiving breakthrough designations seem just as unclear as investors about the value of the program.
You may also be interested in...
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.
Collaboration on GITR immune checkpoint inhibitors includes an extra $100 million if candidates gain FDA breakthrough designation.
FDA confidence to devote time and resources for a breakthrough product resonates with investors and analysts, but the real program value in terms of product sales is yet to be seen. Sponsors also must be careful to manage investor expectations once the breakthrough designation is secured.